The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Prospective randomized phase II trial with gemcitabine versus gemcitabine plus sunitinib in advanced pancreatic cancer: A study of the CESAR Central European Society for Anticancer Drug Research-EWIV.
Heike Richly
No relevant relationships to disclose
Luise Maute
No relevant relationships to disclose
Gerhard Heil
No relevant relationships to disclose
Jörn Rüssel
No relevant relationships to disclose
Elke Jäger
No relevant relationships to disclose
Dieter Koeberle
No relevant relationships to disclose
Stefan Fuxius
No relevant relationships to disclose
Karin Weigang-Koehler
No relevant relationships to disclose
Walter Aulitzky
No relevant relationships to disclose
Bernhard Woehrmann
No relevant relationships to disclose
Gernot Georg Hartung
No relevant relationships to disclose
Berta Moritz
No relevant relationships to disclose
Iris Burkholder
No relevant relationships to disclose
Max E. Scheulen
No relevant relationships to disclose
Lothar Bergmann
Honoraria - Astellas Pharma; Novartis; Pfizer; Roche